Platelet-rich plasma for treating dry eye disease – A systematic review and meta-analysis

Simple item page
dc.contributor.authorAkowuah, Prince Kwaku
dc.contributor.authorObinwanne, Chukwuemeka Junior
dc.contributor.authorOwusu, Ebenezer
dc.contributor.authorKyeremeh, Sylvester
dc.contributor.authorBonsu, Kwaku
dc.contributor.authorKarikari, Lucy Akua Afriyie
dc.contributor.authorAkomeah, Felicia Akyaa
dc.contributor.authorNkansah, Ernest Kyei
dc.contributor.authorKobiah-Acquah, Emmanuel
dc.contributor.orcid0000-0003-3657-6768
dc.contributor.orcid0000-0001-5589-9357
dc.contributor.orcid0000-0003-1612-4350
dc.contributor.orcid0000-0002-7916-0175
dc.contributor.orcid0009-0000-1033-7596
dc.contributor.orcid0009-0006-7208-3513
dc.contributor.orcid0000-0002-3803-7218
dc.contributor.orcid0000-0002-5955-7992
dc.date.accessioned2024-05-06T12:51:17Z
dc.date.available2024-05-06T12:51:17Z
dc.date.issued2024-02
dc.descriptionThis article is published in Contact Lens and Anterior Eye, 47(1), 2024; https://doi.org/10.1016/j.clae.2023.102091
dc.description.abstractPurpose Dry eye disease has public health and economic significance. Platelet-rich plasma is rich in anti-inflammatory agents and growth factors, both beneficial for ocular surface repair. This study aimed to conduct a systematic review and meta-analysis to summarize the benefits of platelet-rich plasma for treating dry eye disease and its adverse effects. Methods Prospective comparative studies using platelet-rich plasma as monotherapy for dry eye disease were included for efficacy assessment. Before-after studies were included for adverse events assessment. Data sources included PubMed, Google Scholar, Web of Science, and Scopus. A systematic review and meta-analysis protocol was pre-registered on PROSPERO (CRD42022347982). PRISMA guidelines were followed. The National Health Institute (NIH) quality assessment tool for before-after studies, the Cochrane risk of bias tool (RoB2), and the methodological index for non-randomized studies were used to assess the risk of bias. Heterogeneity was assessed using the I2 statistic. Results 19 studies (10 comparative and 9 before-after) were included in the systematic review and meta-analysis. The occurrence rate of adverse effects was 2.6 % (95 % CI: 0.5 – 4.7). The pooled standardized mean difference (SMD) for dry eye symptoms was 0.81 (95 % CI: 0.25 – 1.37; I2 = 82 %; p < 0.00001; Z = 2.84, p = 0.004); tear quality was 0.44 (95 % CI: 0.06 – 0.81; I2 = 67 %; p = 0.003; Z = 2.26, p = 0.02); tear quantity was 0.45 (95 % CI: 0.03 – 0.88; I2 = 74 %; p = 0.0003; Z = 2.10, p = 0.04); and corneal staining 0.72 (95 % CI: 0.14 – 1.30; I2 = 85 %; p < 0.00001; Z = 2.43, p = 0.02). Conclusion The current study shows that platelet-rich plasma is efficacious in managing dry eye disease, significantly reducing dry eye signs and symptoms. Such significant improvements could translate to improved quality of life.
dc.description.sponsorshipKNUST
dc.identifier.citationContact Lens and Anterior Eye, 47(1), 2024; https://doi.org/10.1016/j.clae.2023.102091
dc.identifier.urihttps://doi.org/10.1016/j.clae.2023.102091
dc.identifier.urihttps://ir.knust.edu.gh/handle/123456789/15702
dc.language.isoen
dc.publisherContact Lens and Anterior Eye
dc.titlePlatelet-rich plasma for treating dry eye disease – A systematic review and meta-analysis
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S1367048423003302-main.pdf
Size:
2.37 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
Articles